VFA
EGRX

Virtus Fund Advisers’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Virtus Fund Advisers’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,117
Closed -$31.7K – 115
2023
Q1 		$31.7K Buy
+1,117
New +$33.2K 0.22% 75

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Virtus Fund Advisers's EGRX Position: Q2 2023 in Review

Virtus Fund Advisers sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2023, closing a stake of 1,117 shares — an estimated $31.7K sold.

Virtus Fund Advisers first reported a position in EGRX in Q1 2023 and held it in 1 quarter. The position peaked at $31.7K in Q1 2023. 126 funds tracked by Wall St. Rank hold EGRX as of Q2 2023.

  • Virtus Fund Advisers reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Virtus Fund Advisers sold 1,117 Eagle Pharmaceuticals, Inc. shares in Q2 2023, an estimated $31.7K.
  • Virtus Fund Advisers first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2023 and held it in 1 quarter.
  • Virtus Fund Advisers's Eagle Pharmaceuticals, Inc. position peaked at $31.7K in Q1 2023.
  • 126 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2023.

Based on Virtus Fund Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.